Torcetrapib
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Torcetrapib (CP-529414) was a drug developed by Pfizer to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.
Mechanism
Torcetrapib is a cholesterylester transfer protein (CETP) inhibitor. This inhibition results in higher HDL cholesterol levels and reduces LDL cholesterol levels. Torcetrapib development began around 1990. The drug was first administered to humans in 1999. Manufacturing at production scale began in Ireland in 2005.[1]
Development and research
Pfizer had previously announced that torcetrapib would be sold in combination with Pfizer's statin, atorvastatin (Lipitor); however, following media and physician criticism, Pfizer had subsequently planned for torcetraipib to be sold independently of Lipitor.[2]
A 2004 trial showed that torcetrapib could increase HDL and lower LDL with and without an added statin.[3]
End of study
On December 2 2006 Pfizer discontinued the pivotal phase III trial evaluating torcetrapib's safety and efficacy because of an increase in mortality and cardiovascular events associated with the drug's use.[4]
The cost of advancing the development of the drug to Phase III was over 800 million dollars.[5]
References
- ↑ "Pfizer Begins Production at Torcetrapib/Atorvastatin Manufacturing Facility" (Press release). Pfizer. June 22 2005. Retrieved 2006-12-03. Check date values in:
|date=(help) - ↑ Berenson, Alex (July 26 2006). "Heart Pill to Be Sold by Itself". Business. The New York Times. Retrieved 2006-12-03. Check date values in:
|date=(help) - ↑ Brousseau, ME (April 8 2004). "Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol". New England Journal of Medicine. 350 (15): 1505&ndash, 1515. PMID 15071125. Retrieved 2006-12-03. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help) - ↑ Berenson, Alex (December 3 2006). "Pfizer Ends Studies on Drug for Heart Diseas". The New York Times. Retrieved 2006-12-03. Check date values in:
|date=(help) (registration required) - ↑ Cutler, D. M. (2007-03-29). "The Demise of the Blockbuster?" (HTML). The New England Journal of Medicine. Massachusetts Medical Society. 356: 1292–1293. ISSN: 1533-4406. Retrieved 2007-04-23. Check date values in:
|date=(help)
- Clark, RW (January 22 2004). "Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib". Arteriosclerosis, Thrombosis, and Vascular Biology. 24 (3): 490&ndash, 497. PMID 14739125. Retrieved 2006-12-03. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help)
- Clark, RW (2006). "Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action". Journal of Lipid Research. 47 (3): 537&ndash, 552. PMID 16326978. Retrieved 2006-12-03. Unknown parameter
|month=ignored (help); Unknown parameter|coauthors=ignored (help)
- Davidson, MH (November 7 2006). "Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels". Journal of the American College of Cardiology. 48 (9): 1774&ndash, 1781. PMID 17084249. Retrieved 2006-12-03. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help)
- McKenny, JM (November 7 2006). "Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin". Journal of the American College of Cardiology. 48 (9): 1782&ndash, 1790. PMID 17084250. Retrieved 2006-12-03. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help)